NASDAQ Stock Under 5 Stock
—Risk Factors.” Readers are urged to carefully review and consider the
various disclosures made by us in this Report and in our other reports previously filed with the Securities and Exchange Commission, including our periodic reports on Forms 10-QSB and 8-K, and those described from time to time in our press releases
and other communications, which attempt to advise interested ...
more
AtheroGenics is a research-based pharmaceutical company incorporated in the State of Georgia
in 1993. We are focused on the discovery, development and commercialization of novel drugs for the
treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant
rejection, rheumatoid arthritis and asthma. We have developed a proprietary ...
more
This annual report on
Form 10-K contains
forward-looking statements that involve risks and uncertainties.
Forward-looking statements include statements about our product
development and commercialization goals and expectations,
potential market opportunities, our plans for and anticipated
results of our clinical development activities and the potential ...
more
We
are an early-stage biotech company that focuses on discovering and developing new
drugs that address critical unmet medical needs in the areas of thrombocytopenia, cancer, hepatitis
C, hormone-related diseases, osteoporosis and inflammatory diseases. We strive to develop drugs
that are more effective and/or safer than existing therapies, that are more ...
more
The fabrication of integrated circuits is a highly complex and technically demanding process. Defects in designs, problems associated with transitions to newer manufacturing processes and the inadvertent use of
defective or contaminated materials can result in unacceptable manufacturing yields and performance. These problems are frequently difficult to detect in the early stages of the ...
more
Encysive Pharmaceuticals Inc. is a global biopharmaceutical company that engages in the
discovery, development and commercialization of novel, synthetic, small molecule compounds to
address unmet medical needs. We focus our research and development programs predominantly on the
treatment and prevention of interrelated diseases of the vascular endothelium and ...
more
We have included or incorporated by
reference into this Annual Report on Form 10-K statements that may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by
words including “anticipate,” “believe,” “intends,” “estimates,” ...
more
Cognos Incorporated
(“Cognos” or the “Corporation”), a Canadian corporation founded in
1969, is a global leader in business intelligence (“BI”) and corporate
performance management (“CPM”) software solutions. Our solutions help improve
business performance by enabling planned performance management, supported by effective
decision-making at all levels of ...
more
Development Company (“BDC”) pursuant to the provisions
of section 54(a) of the Investment Company Act of 1940 (the (“Act”), to be
subject to the provisions of section 55 through 65 of the Act. The Company has determined
that its operating model best approximates that of an investment company and intends to
make investments into developing businesses in the oil and gas and ...
more
We are a designer, developer and marketer of integrated circuits (ICs) for digital media
applications, such as digital television, LCD TV and digital set-top boxes (STB). Since 1987 we
have designed, developed and marketed very large-scale ICs for graphics applications, historically
for the personal computer (PC) market, and since 1999 for digitally processed ...
more
